GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf; GlaxoSmithKline) for the treatment of adults with relapsed or refractory multiple ...

GSK is setting a new standard for speed when it comes to withdrawing an accelerated approval after a confirmatory trial failure. The British drugmaker is pulling Blenrep off the U.S. market just ...

(RTTNews) - GlaxoSmithKline plc (GSK.L, GSK) announced Thursday that the US Food and Drug Administration has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult ...

During the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) meeting this July, the CHMP recommended the approval of two biologics and one biosimilar: GlaxoSmithKline’s Blenrep ...